NEXGEL, INC.NXGLEarnings & Financial Report
NEXGEL, INC. is a specialty consumer healthcare and medical technology firm that develops, manufactures and distributes ultra-gentle, irritation-free hydrogel products. Its offerings span over-the-counter skincare remedies, wound care solutions, and topical drug delivery platforms, serving consumer, clinical and pharmaceutical partner segments primarily across North America, with growing global distribution channels.
NXGL Q4 FY2025 Key Financial Metrics
Revenue
$2.8M
Gross Profit
$820.0K
Operating Profit
$-1.2M
Net Profit
$-970.0K
Gross Margin
29.3%
Operating Margin
-43.4%
Net Margin
-34.7%
YoY Growth
-8.1%
EPS
$-0.12
NEXGEL, INC. Q4 FY2025 Financial Summary
NEXGEL, INC. reported revenue of $2.8M (down 8.1% YoY) for Q4 FY2025, with a net profit of $-970.0K (down 14.1% YoY) (-34.7% margin). Cost of goods sold was $2.0M, operating expenses totaled $2.0M.
Key Financial Metrics
| Total Revenue | $2.8M |
|---|---|
| Net Profit | $-970.0K |
| Gross Margin | 29.3% |
| Operating Margin | -43.4% |
| Report Period | Q4 FY2025 |
NEXGEL, INC. Annual Revenue by Year
NEXGEL, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $11.4M).
NEXGEL, INC. Quarterly Revenue & Net Profit History
NEXGEL, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.8M | -8.1% | $-970.0K | -34.7% |
| Q3 FY2025 | $2.9M | -0.2% | $-653.0K | -22.3% |
| Q2 FY2025 | $2.9M | +100.3% | $-665.0K | -23.1% |
| Q1 FY2025 | $2.8M | +121.6% | $-712.0K | -25.4% |
| Q4 FY2024 | $3.0M | +181.4% | $-850.0K | -27.9% |
| Q3 FY2024 | $2.9M | +140.8% | $-693.0K | -23.6% |
| Q2 FY2024 | $1.4M | +23.4% | $-885.0K | -61.5% |
| Q1 FY2024 | $1.3M | +104.2% | $-853.0K | -67.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.4M | $2.9M | $3.0M | $2.8M | $2.9M | $2.9M | $2.8M |
| YoY Growth | 104.2% | 23.4% | 140.8% | 181.4% | 121.6% | 100.3% | -0.2% | -8.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.4M | $9.8M | $10.6M | $11.0M | $10.4M | $9.7M | $11.6M | $10.5M |
| Liabilities | $5.2M | $5.2M | $5.6M | $4.9M | $4.9M | $4.7M | $6.0M | $5.6M |
| Equity | $4.8M | $4.2M | $4.7M | $5.8M | $5.2M | $4.7M | $5.2M | $4.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.1M | $-700000 | $-1.2M | $-859000 | $-400000 | $-407000 | $-785000 | $281000 |